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Calcium-regulated parathyroid hormone release in patients with mild
or advanced secondary hyperparathyroidism. Differences in the regula-
tion of parathyroid hormone (PTH) release by calcium are thought to
account for excess PTH secretion in patients with secondary hyperpara-
thyroidism (2°HPTH). To determine whether calcium-regulated PTH
release varies with the severity of 2°HPTH in patients with end-stage renal
disease, dynamic tests of parathyroid gland function were done using the
four-parameter model in 26 patients with 2°HPTH documented by bone
biopsy. Estimates of the set point did not differ among patients catego-
rized as mild (basal serum PTH < 400 pg/ml), moderate (basal PTH 400
to 600 pg/mI) or severe (basal PTH > 600 pg/mI) 2°HPTH; values were
1.23 0.06 mmol/liter, 1.24 0.06 mmol/liter and 1.23 0.05 mmol/liter,
respectively, and none of these set point estimates differed from results
obtained in normal volunteers, 1.21 0.02 mmollliter (NS). The slope of
the sigmoidal ionized calcium-PTH curve also did not differ among
groups. Set point values did not correspond to basal serum PTH levels, to
the maximum serum PTH level observed during hypocalcemia or to the
minimum serum PTH level seen during hypercalcemia in patients with
2°HPTH. In contrast, basal serum PTH values were positively correlated
with both the maximum serum PTH level observed during hypocalcemia
(r = 0.76, P < 0.01), and the minimum serum PTH level attained during
calcium infusions (r = 0.78, P < 0.01). Calcium-regulated PTH release
does not differ with the degree of 2°HPTH, and set point abnormalities do
not account for excess PTH secretion in patients with chronic renal failure
as judged by in vivo dynamic tests of parathyroid gland function. The
results suggest that variations in parathyroid gland size are the major
contributor to excessive PTH secretion in patients with chronic renal
failure.
Disturbances in the regulation of parathyroid hormone (PTH)
secretion by calcium are thought to contribute to the development
and progression of secondary hyperparathyroidism in patients
with chronic renal failure [1—4]. Studies by Brown and co-workers
initially suggested that parathyroid cells obtained from uremic
patients with secondary hyperparathyroidism were less sensitive to
the suppressive effect of calcium on PTH release in vitro [4], and
similar findings were reported using tissues from patients with
primary hyperparathyroidism due to parathyroid adenoma or
primary parathyroid gland hyperplasia [5, 6]. Subsequent studies
confirmed that the in vivo regulation of PTH release by calcium
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was abnormal in patients with primary hyperparathyroidism [7],
but two recent reports have failed to document in vivo differences
in calcium-regulated PTH release between normal subjects and
patients with secondary hyperparathyroidism due to chronic renal
failure [8, 9].
Because the extent of parathyroid gland hyperplasia varies
widely in end-stage renal disease, the control of PTH secretion
may be abnormal in some but not all patients with secondary
hyperparathyroidism, thereby accounting for the failure to detect
differences from normal in unselected patients [8, 9]. In this
regard, several reports indicate that the nodular histologic pattern
of parathyroid hyperplasia is associated with greater glandular
enlargement in dialysis patients undergoing parathyroidectomy
for the management of secondary hyperparathyroidism [10, 11],
and Fukuda et al found that vitamin D-receptor expression was
lower in tissues with a nodular rather than diffuse histologic
pattern of hyperplasia using immunohistochemical methods [11].
Calcium-regulated PTH release may differ, therefore, in mild and
severe secondary hyperparathyroidism due to variations in both
the histologic subtype and degree of parathyroid gland hyperpla-
sia.
To investigate this possibility, dynamic tests of parathyroid
gland function were done using the four-parameter model devel-
oped by Brown and associates in 26 patients undergoing regular
dialysis with varying degrees of secondary hyperparathyroidism
confirmed by bone biopsy [8, 121. Calcium-regulated PTH release
was assessed in those with mild or severe secondary hyperpara-
thyroidism, and the results from each group were compared with
data obtained in normal volunteer subjects.
Methods
Only patients with chronic renal failure and secondary hyper-
parathyroidism documented by bone biopsy were included in the
study. Bone biopsies were obtained from the iliac crest after
double tetracycline labeling, and the skeletal lesions of renal
osteodystrophy were classified using histomorphometric criteria
reported previously [13]; 25 patients had overt osteitis fibrosa and
one had a mild lesion of secondary hyperparathyroidism. None of
the patients had histochemical evidence of aluminum deposition
in bone, and none was taking aluminum-containing medications
regularly. The mean age of the patients was 16.4 5.2 years
(range 9 to 38 years); there were 14 female and 12 male subjects.
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All patients were managed by continuous cycling peritoneal
dialysis (CCPD), and the duration of dialysis prior to study was 25
30 months. The concentration of calcium in peritoneal dialysate
was 3.5 mEq/liter. All patients had previously been treated with
daily oral doses of calcitriol, but vitamin D therapy was discon-
tinued four weeks before undergoing tests of parathyroid gland
function.
Subjects were evaluated during two day admissions to the
General Clinical Research Center (GCRC) at UCLA as previ-
ously described [8]. On the first day of study, serum ionized
calcium levels were lowered during two-hour intravenous infu-
sions of sodium citrate to achieve a progressive decline in ionized
calcium to a concentration at least 0.2 mmol/liter below pre-
infusion values; the dose of sodium citrate ranged from 28 to 118
mg/kg/hr [8, 14]. Blood samples for measurements of ionized
calcium and PTH were obtained 30, 15 and 0 minutes before and
every 10 minutes during sodium citrate infusions.
The following day, serum ionized calcium levels were raised
during two-hour intravenous infusions of 10% calcium gluconate
to achieve a progressive rise in ionized calcium to a level 0.2
mmol/liter above pre-infusion values. The dose of calcium glu-
conate ranged from 2 to 8 mg/kg/hr [8]. Blood samples for
measurements of ionized calcium and PTH were obtained as
described previously for infusions of sodium citrate. On each day
of testing, the average of the three measurements obtained 30, 15
and 0 minutes before the start of infusions was used as the basal
value for both serum ionized calcium and PTH.
During all infusions, serum ionized calcium levels were moni-
tored using a calcium-specific electrode (Radiometer ICA-Il,
Copenhagen, Denmark); blood samples were collected anaerobi-
cally, and measurements were obtained immediately thereafter.
Serum samples for PTH determinations were separated by cen-
trifugation immediately after collection, snap frozen on solid CO2,
and stored at —70°C. until assay. Serum ionized calcium levels
were monitored after the end of infusions until values returned to
baseline levels. None of the patients underwent dialysis during any
of the infusions.
Results obtained from dynamic tests of PTH secretion in twenty
normal human volunteers are provided for reference [8]. The
mean age of volunteer subjects was 21 two years; eleven were
women and nine were men [8]. All studies were approved by the
UCLA Human Subjects Protection Committee, and written in-
formed consent was obtained from all patients and volunteers.
Biochemical determinations
Determinations of calcium, ionized calcium, phosphorus, alka-
line phosphatase, calcitriol and PTH levels in serum were done
using methods described elsewhere [8, 13]. Serum PTH levels
were measured using an immunoradiometric assay for the intact
[1—84] hormone [15], and serum calcitriol levels were determined
by radioreceptor assay [161.
Statistical analysis
All data are expressed as the mean standard error. Compar-
isons among groups were done using analysis of variance with
contrasts or unpaired t-tests [17]. Basal serum ionized calcium and
PTH values represent the average of three separate determina-
tions obtained before the start of sodium citrate or calcium
gluconate infusions. Results obtained during infusions of either
sodium citrate or calcium gluconate were evaluated using analysis
of variance for repeated measures and paired t-tests with appro-
priate correction for multiple comparisons between groups [17].
The sigmoidal curve that describes the relationship between
serum ionized calcium and PTH levels was generated using the
four parameter model described previously [12]. For this analysis,
the set-point for calcium-regulated PTH release is the concentra-
tion of ionized calcium in serum at which the serum PTH level is
midway between the maximum value achieved during hypocalce-
mia and the minimum value attained during hypercalcemia [12].
Results
Basal serum PTH levels ranged from 138 to 2103 pg/ml in the
26 patients evaluated, and the mean value was 704 245 pg/mI.
Only one patient had a baseline serum PTH level below 200
pg/ml; this subject had bone biopsy findings of a mild lesion of
secondary hyperparathyroidism, whereas each of the remaining 25
patients had a basal serum PTH level above 200 pg/ml and
histologic changes of osteitis fibrosa. Overall, baseline serum PTH
levels were positively correlated with the histologic severity of
secondary hyperparathyroidism as judged by the measured rate of
bone formation (r = 0.54, P < 0.05).
Estimates of the set point obtained using the four parameter
model ranged from 1.10 to 1.31 mmol/liter in patients with
secondary hyperparathyroidism. The mean value for the set point
was 1.23 0.05 mmol/liter, and this did not differ from that
established in 20 volunteer subjects with normal renal function,
1.21 0.2 mmol/liter (NS) [8].
To determine whether the set point for calcium-regulated PTH
release varies as a function of the severity of secondary hyperpara-
thyroidism, subjects were categorized using individual basal values
for serum PTH according to the following criteria: mild, PTH
<400 pg/ml (N = 6); moderate, PTH >400 but <600 pg/ml (N =
6); and severe, PTH >600 pg/ml (N = 14). Mean serum PTH
levels in these three groups were 225 28, 493 34 and 1001
95 pg/mi, respectively, and both the rate of bone formation and
the extent of eroded bone perimeter rose according to the basal
level of PTH in serum (Table 1). There were no differences among
groups in the serum levels of total calcium, ionized calcium or
phosphorus (Table 1). Similarly, the mean age of patients did not
differ, whereas the duration of regular dialysis tended to be
greater in those with the highest serum PTH levels (Table 1). The
proportion of male and female subjects in each subgroup did not
differ substantially (X2 = 5.11, NS; Table 1).
Mean values for the set point were 1.23 0.06 mmoi/liter, 1.24
0.06 mmol/liter and 1.23 0.05 mmol/liter in patients with
mild, moderate or severe secondary hyperparathyroidism, respec-
tively (Fig. 1), and there was no relationship between the values
for set point and the basal levels of PTH in serum (Fig. 2). Neither
the maximum serum PTH level obtained during citrate-induced
hypocalcemia nor the minimum serum PTH level obtained during
infusions of calcium gluconate correlated with estimates of the set
point (Fig. 3). In contrast, baseline serum PTH levels correlated
positively with both the maximum PTH value achieved during
hypocaicemia (r = 0.76, P < 0.01) and the minimum PTH level
observed during calcium infusions (r = 0.78, P < 0.01; Fig. 4).
The slope of the sigmoidal curve depicting the relationship
between serum ionized calcium and PTH levels also did not differ
with the severity of secondary hyperparathyroidism (Fig. 5).
Estimates of the slope were 103 26, 91 27 and 95 43
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Table 1. Characteristics of 26 patients with secondary hyperparathyroidism categorized according to basal serum PTH levels
Mild
PTH < 400 pg/ml
Moderate
PTH 400—600 pg/ml
Severe
PTH > 600 pg/mI
Normal
subjects
Bone formation rate pm2/mm2lday 668 78 861 92 1232 141 —
Eroded bone perimeter % 6.8 1.1 8.0 1.1 10.7 0.9 —
Total calcium g/dl 8.6 0.5 9.2 0.4 9.1 0.2 9.0 0.3
Ionized calcium mmol/liter 1.21 0.05 1.21 0.03 1.22 0.02 1.22 0.04
Phosphorus mg/dl 6.2 0.6 6.7 0.5 6.2 0.3 3.6 0.4
Age years 13.8 1.0 15.1 0.7 18.1 1.7 21 2
Dialysis duration months 15 7 23 8 30 11 —
Males/females 5/1 3/3 4/10 2/11
Normal reference values are: bone formation rate, 97 to 613 um2/mm2/day; eroded bone perimeter, 0.5 to 4.3%.
$
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pg/ml/mmol in patients with mild, moderate or severe secondary
hyperparathyroidism, respectively.
Additional analyses were completed for subjects with the
highest basal serum PTH values. Of the 14 patients with baseline
PTH levels above 600 pg/mi, eight had values between 600 and
1000 pg/mi, whereas six had values exceeding 1000 pg/mi. Al-
though basal serum PTH levels averaged 750 73 pg/ml and 1335
281 pg/ml, respectively, in these two groups, corresponding
estimates of the set point were 1.23 0.02 and 1.20 0.03
pg/ml/mmol, and neither value differed from those obtained in
patients with either mild or moderate secondary hyperparathy-
roidism or from values determined in normal volunteers.
Discussion
The results of the current study indicate that the set point for
calcium-regulated PTH release does not vary with the severity of
secondary hyperparathyroidism in patients with end-stage renal
disease undergoing regular dialysis. Set point estimates were quite
similar in subjects with mild or severe secondary hyperparathy-
roidism, and the mean value for all patients did not differ from
that for subjects with normal renal function. Set point values in
individual patients did not correspond with the basal level of PTH
in serum, and neither the maximum serum PTH level achieved
during hypocalcemia nor the minimum serum PTH level attained
during hypercalcemia correlated with in vivo estimates of the set
point. Such findings indicate that disturbances in the regulation of
PTH release by calcium do not account for the markedly elevated
serum PTH levels that characterize patients with secondary
hyperparathyroidism due to chronic renal failure.
At least two distinct mechanisms are thought to contribute to
excess PTH secretion in patients with secondary hyperparathy-
roidism: enlargement of the parathyroid glands and alterations in
the regulation of PTH secretion by parathyroid cells. Parathyroid
hyperpiasia is common in patients with chronic renal failure, and
Szabo et al demonstrated that the administration of calcitriol to
rats with renal failure diminished both the incorporation of
tritiated thymidine into DNA and the weight of the parathyroid
glands from values determined in untreated controls [18]. More-
over, calcitriol, but not calcium, has been reported to lower the
rate of cell proliferation and proto-oncogene expression in pri-
mary cultures of bovine parathyroid cells [19]. Thus, calcitriol acts
as an important regulator of parathyroid growth, and its relative
deficiency in chronic renal failure would favor the development of
tissue hyperplasia.
In addition to parathyroid gland hyperplasia, disturbances in
the regulation of PTH release by calcium have also been impli-
cated as a cause of excess PTH secretion in patients with chronic
renal failure. Using a four parameter model to examine the
sigmoidal relationship between ionized calcium levels and PTH
secretion in vitro, Brown and co-workers originally suggested that
calcium-regulated PTH release was abnormal in dispersed para-
thyroid cells obtained from patients with hyperplastic parathyroid
glands or parathyroid adenomas [5, 6, 12]. Harris et al and others
subsequently reported higher than normal set point values for
calcium-regulated PTH release in vivo in patients with primary
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Fig. 1. Set point values for volunteer subjects with normal renal function and
for patients categorized as having mild, moderate or severe secondary
hypeiparathyroidism as judged by basal serum PTH levels. The horizontal
dashed line depicts the average set point for all 26 patients with bone
biopsy-proven secondary hyperparathyroidism.
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Fig. 2. The relationship between estimates of the set point and the basal level
of PTH in serum in 26 patients with secondary hypeiparathyroidism docu-
mented by bone biopsy (r =
—0.18).
1556 Goodman et al: PTH secretion in seconda,y hyperparathyroidism
.
• 4
I I I
1.00 1.10 1.20 1.30 1.40 1.50
Set point, mmoI/iiter
4,000
3,500
3,000
2,500
2,000
1,500
1,000
500
0
0 500 1,000 1,500 2,000
Basal serum PTH, pg/mi
hyperparathyroidism [7, 20]. These findings supported a patho-
physiologic role for set point abnormalities as a cause of excess
PTH secretion in hyperparathyroid states; projections based upon
the four parameter model also favored a set point disturbance as
the most likely explanation for the markedly elevated serum PTH
levels found in patients with secondary hyperparathyroidism [121.
In contrast to the data available in primary hyperparathyroid-
ism, two recent in vivo studies have failed to document distur-
bances in calcium-regulated PTH release in patients with second-
ary hyperparathyroidism [8, 9]. Messa Ct al evaluated subjects with
stable chronic renal failure, whereas Ramirez et al studied
patients undergoing regular peritoneal dialysis; estimates of the
set point obtained using the four parameter model did not differ,
however, in either group of patients from values determined in
volunteer subjects with normal renal function [8, 9]. Such findings
are in sharp contrast to results reported elsewhere in hemodialysis
patients with secondary hyperparathyroidism, but previous studies
have utilized methods of data analysis that differ substantially
from the four parameter model. Moreover, results obtained in
normal subjects using these modified techniques have not been
provided for comparison [21—24]. Both the definition of the set
point and the methods used to elicit changes in serum ionized
calcium have varied considerably among different groups of
investigators, and these methodologic considerations have re-
cently been reviewed in detail [25].
Nevertheless, it is possible that abnormalities in the control of
PTH secretion are confined to those with more advanced disease.
Previous studies in patients with chronic renal failure have not
examined the relationship between the severity of secondary
hyperparathyroidism and the regulation of PTH release by cal-
cium [8, 9].
The results of the current investigation demonstrate that calci-
um-regulated PTH release does not differ in those with mild or
severe secondary hyperparathyroidism. There was no evidence of
a bimodal distribution of values for the set point, and estimates of
the set point did not correlate with the biochemical severity of
secondary hyperparathyroidism as judged by the basal levels of
PTH in serum, the maximum serum PTH level observed during
citrate-induced hypocalcemia or the degree of PTH suppression
achieved during infusions of calcium gluconate. In contrast, basal
serum PTH levels, which generally correspond to the overall
degree of parathyroid gland enlargement [261, correlated with
both the maximum serum PTH level achieved during hypocalce-
mia and the minimum serum PTH level observed during hyper-
calcemia. The data suggest, therefore, that the degree of parathy-
roid hyperplasia, rather than alterations in the regulation of PTH
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Fig. 4. The relationship between the basal level of PTH in serum and the
maximum serum PTH level observed during citrate-induced hypocalcemia
(r = 0.76, P < 0.01) (A) or the minimum serum PTH level attained during
infusions of calcium gluconate, (r = 0.78, P < 0.01) (B) in 26 patients with
secondary hyperparathyroidism.
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Fig. 3. The relationship between values for the set point and the maximum
serum PTH level observed during citrate-induced hypocalcemia (A, r = 0.16)
or the minimum serum PTH level attained during infusions of calcium
gluconate (B, r = 0.13) in 26 patients with secondary hypeiparathyroidism.
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release by calcium, largely accounts for the elevated serum PTH
levels of patients with secondary hyperparathyroidism due to
chronic renal failure. Similar findings were reported by McCarron
et a! in patients with persistent secondary hyperparathyroidism
following renal transplantation [27].
The current results in patients with end-stage renal disease are
consistent with data presented by Hendy et al in dogs with
secondary hyperparathyroidism induced by vitamin D deficiency
[28]. In this report, the parathyroid glands were enlarged, serum
PTH levels were substantially elevated and the amount of mRNA
for pre-pro-PTH in parathyroid tissue was greater in vitamin
D-deficient animals than in vitamin D replete controls. The set
point for calcium-regulated PTH release did not differ, however,
from control values in the group with secondary hyperparathy-
roidism when assessed using the four parameter model [28j.
Similar results were reported by Cloutier, Gascon-Barre and
D'Amour [29]. These experimental findings, and those of the
current clinical investigation, are consistent with in vivo studies in
the rat which demonstrate no differences from control values in
mRNA levels for the membrane-associated calcium receptor in
two experimental models of secondary hyperparathyroidism [30].
Therefore, the molecular mechanism for calcium-dependent sig-
nal transduction in the control of PTH release appears to be intact
in hyperplastic parathyroid tissues [30]. Since parathyroid cells
exhibit basal rates of PTH release despite high ambient calcium
concentrations [4, 5, 31], a marked increase in parathyroid cell
number in hyperplastic glands may be sufficient to maintain
persistently high serum PTH levels in vivo without an associated
disturbance in the regulation of PTH release by calcium [32].
Recent observations indicate that vitamin D receptor expres-
sion is lower in hyperplastic parathyroid tissues with a nodular
histologic pattern compared to those with diffuse chief cell
hyperplasia [11]. Fukuda et a! noted an inverse relationship
between the level of vitamin D receptor expression as measured
by immunohistochemical methods and the weight of the parathy-
roid glands in patients undergoing parathyroidectomy for the
management of renal osteodystrophy [1 1]. Although adequate
control data from normal parathyroid tissues was not reported
[11], variations in vitamin D receptor expression could represent
an important determinant of the degree of parathyroid gland
hyperplasia in patients with end-stage renal disease, perhaps by
modifying the inhibitory actions of 1,25-dihydroxyvitamin D on
parathyroid cell proliferation or by permitting clonal expansion
within hyperplastic tissues [18, 19, 33]. Accordingly, the develop-
ment of parathyroid gland hyperplasia rather than disturbances in
the control of PTH secretion may be the predominant manifes-
tation of calcitriol deficiency in chronic renal failure. This view is
consistent with evidence that calcitriol lowers the rate of gene
transcription for pre-pro-PTH but does not directly modify the
release of PTH from parathyroid cells in short-term studies in
vitro [34].
Unfortunately, information about the size and histology of the
1.40 parathyroid glands was not available for patients enrolled in the
current study since only two of the 26 subjects evaluated subse-
quently underwent parathyroidectomy, As such, it is not known
whether the nodular form of parathyroid hyperplasia was more
common in those with severe secondary hyperparathyroidism or
whether patients with the highest basal serum PTH levels indeed
had more extensive parathyroid gland hyperplasia, as suggested by
previous studies [26, 35, 36]. It should be noted, however, that the
two patients from the current study who did undergo parathyroid-
ectomy had set point estimates of 1.25 and 1.31 mmol/liter,
respectively. Both values exceeded the overall group mean for
patients with secondary hyperparathyroidism, and one of these
was the highest observed among the 26 subjects. It is possible,
therefore, that the regulation of PTH release by calcium differs in
the nodular and diffuse forms of parathyroid gland hyperplasia,
but there are currently no data that address this issue.
In summary, variations in the control of PTH release by calcium
do not contribute substantially to the biochemical severity of
secondary hyperparathyroidism in patients undergoing regular
dialysis as judged by in vivo dynamic tests of parathyroid gland
function. Despite recognized limitations in the interpretation of in
vivo assessments of parathyroid gland function [25], the concept
that the set point for calcium-regulated PTH release is abnormal
in chronic renal failure is not supported by currently available
experimental evidence. Rather, the degree of parathyroid gland
enlargement may be a more important determinant of the severity
of secondary hyperparathyroidism in patients with end-stage renal
disease. Efforts designed to reduce or prevent the development of
parathyroid gland hyperplasia, particularly during the early stages
of progressive renal disease, are likely to favorably affect the
long-term control of secondary hyperparathyroidism in patients
with chronic renal failure.
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